Table 1

Summary of ongoing clinical trials targeting dry AMD

Drug category/name	Clinical trial ID (NCT #)	Study phase	Route of delivery	Status	Sponsor	Location	Number of patients
Antioxidative
AREDS	NCT00000145	Phase III	Oral	Completed	National Eye Institute (NEI)	USA	3640
AREDS2	NCT00345176	Phase III	Oral	Completed	National Eye Institute (NEI)	USA	4203
OT-551	NCT00306488	Phase II	Topical	Completed	National Institutes of Health Clinical Center (CC)	USA	11
Reduction of toxic bryproducts
GSK933776	NCT01342926	Phase II	IV	Completed	GlaxoSmithKline	USA	191
RN6G	NCT01577381	Phase II	IV	Terminated	Pfizer	USA	10
Visual cycle modulators
ACU-4429	NCT01802866	Phase IIb/III	Oral	Completed	Kutoba Vision Inc	USA	508
Fenretinide	NCT00429936	Phase II	Oral	Completed	Sirion Therapeutics, Inc	USA	246
C20-D3-vitamin A (ALK-001)	NCT03845582	Phase III	Oral	Ongoing—recruiting	Alkeus Pharmaceuticals, Inc	USA	300
Anti-inflammatory and complement inhibition
Eculizumab	NCT00935883	Phase II	IV	Completed	Philip J. Rosenfeld, MD	USA	30
Lampalizumab	NCT02247531	Phase III	Intravitreal	Terminated	Hoffman-La Roche	Multicenter	906
Lampalizumab	NCT02247479	Phase III	Intravitreal	Terminated	Hoffman-La Roche	Multicenter	975
Sirolimus (rapamycin)	NCT00766649	Phase I/II	Subconjunctival	Completed	National Eye Institute (NEI)	USA	11
Avacincaptad pegol (Zimura)	NCT02686658	Phase II/III	Intravitreal	Completed	IVERIC bio, Inc.	Multicenter	286
Pegcetacoplan (APL-2)	NCT02503332	Phase II	Intravitreal	Completed	Apellis Pharmaceuticals Inc.	Multicenter	246
Pegcetacoplan (APL-2)	NCT03525600	Phase III	Intravitreal	Ongoing—not recruiting	Apellis Pharmaceuticals Inc.	Multicenter	600
Pegcetacoplan (APL-2)	NCT03525613	Phase III	Intravitreal	Ongoing—not recruiting	Apellis Pharmaceuticals Inc.	Multicenter	600
Tedisolumab (LFG316)	NCT01527500	Phase II	Intravitreal	Completed	Novartis Pharmaceuticals	USA	150
Risuteganib	NCT03626636	Phase II	Intravitreal	Completed	Allegro Ophthalmics	USA	42
Neuroprotection
Ciliary nerve trophic factor	NCT00063765	Phase I	Intravitreal	Completed	National Eye Institute (NEI)	USA	10
Ciliary nerve trophic factor	NCT00447954	Phase II	Intravitreal	Completed	Neurotech Pharmaceuticals	USA	51
Brimonidine tartrate	NCT00658619	Phase II	Intravitreal	Completed	Allergan	Multicenter	113
Brimonidine tartrate	NCT02087085	Phase IIb	Intravitreal	Terminated	Allergan	Multicenter	303
Gene therapy
AAVCAGsCD59	NCT03144999	Phase I	Intravitreal	Completed	Hemera Biosciences	USA	17
GT005	NCT03846193	Phase I/II	Subretinal	Ongoing - Recruiting	Gyroscope Therapeutics	UK	35
Cell-based therapies
Palucorcel (CNTO-2476)	NCT01226628	Phase I/II	Subretinal	Completed	Janssen Research & Development, LLC	USA	35
MA09-hRPE	NCT01344993	Phase I/II	Subretinal	Completed	Astelas Institute for Regenerative Medicine	USA	9
CPCB-RPE1	NCT02590692	Phase I/IIa	Subretinal	Ongoing—not recruiting	Regenerative Patch Technologies	USA	16
Mitochondrial enhancers
Elamipretide	NCT02848313	Phase I	Subcutaneous	Completed	Stealth Biotechnologies Inc	USA	40
Elamipretide	NCT03891875	Phase II	Subcutaneous	Ongoing—recruiting	Stealth Biotechnologies Inc	USA	180
Nanosecond laser therapy
2RT nanosecond laser	NCT01790802	Not applicable	Retinal active laser therapy	Completed	Center for Eye Research Australia	Australia	292

AMD, age-related macular degeneration.